Portfolio update: I’m currently down ~28% on Novo Nordisk this year.
But I’m not waving a white flag — because sometimes a drop reveals opportunity, not failure. š The question: “Is this slump meaningful, or has the market over-corrected?” Based on the latest numbers, my view is that Novo Nordisk is fairly valued to slightly undervalued — meaning I’m comfortable holding and believe there’s potential upside, but this isn’t a free-lunch scenario. Staying focused, tracking the story, and playing the long game. #Investing #HealthCare #ValueMindset Valuation Snapshot & Commentary Here are the key points on Novo Nordisk’s valuation and risks: Positive signals (supporting undervaluation/hold): Trailing P/E is around ~14.3× and the forward P/E ~14.3-15× in many estimates. StockAnalysis +2 StockAnalysis +2 The company has a strong market position in diabetes and obesity treatments (e.g., drugs like Ozempic and Wegovy) and global scale. Morningstar +1 Caution/overhangs (why it might not be cheap): Novo Nordisk recently cut its full-...